Актуальность применения психотропных препаратов в клинической онкологии


Ю.Н. Зубкова, И.А. Курмуков, О.А. Обухова, Ш.Р. Кашия

Отдел функциональной диагностики, интенсивной терапии и реабилитации, Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина (НМИЦ онкологии им. Н.Н. Блохина), Москва, Россия
Представлен обзор основных зарубежных исследований и рекомендаций, обосновавших формирование психоонкологии – новой субспециальности на стыке онкологии и психиатрии. Психиатрические расстройства у пациентов с онкологическими заболеваниями встречаются значительно чаще, чем в общей популяции, что связано с развитием расстройств адаптации и депрессией. Даже коморбидность шизофрении и расстройств шизофренического спектра у пациентов с онкологическими заболеваниями составляет около 3–4%, а психиатрические симптомы на разных стадиях лечения наблюдаются не менее чем у 30% больных. Назначение психотропных препаратов играет также важную роль и при оказании паллиативной помощи.
К специфическим особенностям онкопсихиатрии относятся диагностика психических расстройств у больных тяжелой соматической патологией, дифференциальная диагностика клинически схожих симптомов и побочных эффектов противоопухолевого и психиатрического лечения, учет потенциальных взаимодействий лекарственных препаратов, используемых в психиатрии и онкологии, определение целесообразности применения психофармакологических средств по непсихиатрическим показаниям.

Литература


1. Henry G.W. Some modern aspects of psychiatry in general hospital practice. Am. J. Psychiatry. 1929;86:481–99.

2. Lipowski Z.J. Consultation-liaison psychiatry at century’s end. Psychosomatics. 1992;33:128–33. Doi: 10.1176/ajp.131.6.623.

3. Patterson K.R. Psycho-Oncology. In: Psychosomatic medicine. K.D. Ackerman, A.F. DiMartini (ed.). Oxford; New York: Oxford University Press, 2015. P. 365–75.

4. Смулевич А.Б. Психосоматические расстройства в онкологии. Эффективная фармакотерапия. 2009;18:28–9.

5. Sutherland A.M. Psychological impact of cancer and its therapy. Med. Clin. North Am. 1956;40(3):705–20.

6. Plumb M., Holland J. Comparative studies of psychological function in patients with advanced cancer –I Self-reported depressive symptoms. Psychosom. Med. 1977;39:264–76.

7. Maguire G.P., Lee E.G., Bevington D.J., et. al. Psychiatric problems in the first year after mastectomy. Br. Med. J. 1978;15(1):963–65.

8. Plumb M., Holland J. Comparative studies of psychological function in patients with advanced cancer II. Interviewer-rated current and past psychological symptoms. Psychosom. Med. 1981;43:243–54.

9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III). Washington, D.C.: American Psychiatric Publishing, 1980. 494 p.

10. Derogatis L.R., Morrow G.R., Fetting J., et al. The prevalence of psychiatric disorders among cancer patient. JAMA. 1983;249(6):751–57.

11. Hardman A., Maguire P., Crowther D. The recognition of psychiatric morbidity on a medical oncology ward. J. Psychosom. Res. 1989;33:235–39.

12 Razavi D., Delvaux N., Farvacques C., Robaye E. Screening for adjustment disorders and major depressive disorders in cancer in-patients. Br. J. Psychiatry. 1990;156:79–83.

13. Grassi L., Rosti G., Lasalvia A., Marangolo M. Psychosocial variables associated with mental adjustment to cancer. Psycho-Oncology. 1993;2:11–20.

14. Grassi L., Gritti P., Rigatelli M., Gala C. Psychosocial problems secondary to cancer: an Italian multicenter survey of consultation-liason psychiatry in oncology. Eur. J. Cancer. 2000;36:579–85.

15. Kissane D.W., Grabsch B., Love A., et al. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust. N. Z. J. Psychiatry. 2004;38:320–6. PMID: 9734576.

16. Prieto J.M., Blanch J., Atala J., et al. C. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J. Clin. Oncol. 2002;20:1907–17.

17. Singer S., Szalai C., Briest S., et al. Co-morbid mental health conditions in cancer patients at working age – prevalence, risk profiles, and care uptake. Psychooncology. 2013;22(10):2291–97. Doi: 10.1002/pon.3282.

18. Singer S., Das- Munshi J., Brachler E. Prevalence of mental health conditions in cancer patients in acute care-a meta-analysis. Ann. Oncol. 2010;21:925–30. Doi:10.1093/annonc/mdp515.

19. Mitchell A.J., Chan M., Bhatti H., et al. Prevalence of depression, anxiety, and adjustment disorders in oncological, hematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet. Oncol. 2011;12:160–74.

20. Miovic M., Block S. Psychiatric disorders in advanced cancer. Cancer. 2007;110:1665–76. Doi:10.1002/cncr.22980.

21. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Психические расстройства в онкологии (результаты мультицентровой программы «Синтез»). Психические расстройства в общей медицине. 2009;1:4–12.

22. Derogatis L.R., Feldstein M., Morrow G., et al. A survey of psychotropic drug prescriptions in an oncology population. Cancer. 1979;44:1919–29.

23. Jaeger H., Morrow G.R., Carpenter P.J., Brescia F.A survey of psychotropic drug utilization by patients with advanced neoplastic disease. Gen Hosp. Psyciatry. 1985;7:353–60.

24. Stiefel F.C., Kornblith A.B., Holland J.C. Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer. 1990;65:1048–53.

25. Thekdi S.M., Irarrazaval M.E., Dunn L. Psychopharmacological interventions. In: Grassi L,Riba M, editors. Clinical psycho-oncology:an international perspective. Chichester: Wiley, 2012. P. 109–26.

26. Caruso R., Grassi L., Nanni M.G., Riba M. Psychopharmacology in psycho-oncology. Curr. Psychiatry Rep. 2013;15(9):393. Doi:10.1007/s11920-013-0393-0.

27. Farriols C., Ferrandez O., Planas J., et al. Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J. Pain Sympton. Manage. 2012;43:945–52. Doi: 10.1016/j.jpainsymman.2011.05.010.

28. Desplenter F., Bond C., Watson M., et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study. Br. J. Cancer. 2012;107:1644–51. Doi: 10.1038/bjc.2012.364.

29. De Bock G.H., Musters R.F., Bos H.J., et al. Psychotropoc medication during endocrine treatment for breast cancer. Support Care Cancer. 2012;20:1533–40. Doi: 10.1007/s00520-011-1242-5.

30. Ng C.G., Boks M.P., Smeets H.M., et al. Prescription patterns for psychotripic drugs in cancer patients; a large population study in the Netherlands. Psychology. 2013;22:762–67. Doi: 10.1002/pon.3056.

31. Lindqvist O., Lundquist G., Dickman A., et al. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion. J. Palliative Med. 2013;16:38–43. Doi: 10.1089/jpm.2012.0205.

32. Deyell R.J., Lorenzi M., Ma S., et al. Antidepressant use among survives of childhood, adolescent and young adult cancer: a report of the Childhood, Adolescent and Young Adult Cancer Survivor (CAYACS) Research Program. Pediatr. Blood Canc. 2013;60:816–22.

33. Breitbart W., Alici Y. Evidence-based treatment of delirium in patients with cancer. J. Clin. Oncol. 2012;30:1206–14. Doi:10.1200/JCO.2011.39.8784.

34. Rodin G., Lloyd N., Katz M., et al. The treatment of depression in cancer patients: a systematic review. Support Care Cancer. 2007;15(2):123–36.

35. Okamura M., Akizuki N., Nakano T., et al. Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychology. 2008;17(2):154–60.

36. Rayner L., Price A., Evans A., et al. Antidepressants for treatment of depression in palliative care: systematic review and meta-analysis. Palliat. Med. 2011;25(1):36–51. Doi:10.1177/0269216310380764.

37. Rayner L., Price A., Hotopf M., Higginson I.J.The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur. J. Cancer. 2011;47(5):702–12. Doi:10.1016/j.ejca.2010.11.027.

38. Cowan J.D., Palmer T.W. Practical guide to palliative sedation. Curr. Oncol. Rep. 2002;4(3):242–49.

39. Kehl K.A. Treatment of terminal restlessness: a review of the evidence. J. Pain Palliative Care Pharmacother. 2004;18(1):5–30.

40. Grassi L., Caruso R., Hammelef K., et al. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int. Rev. Psychiatry. 2014;26(1):44–62. Doi: 10.3109/09540261.2013.842542.

41. Ouwens M., Hulscher M., Hermens R., et al. Implementation of integrated care for patients with cancer: a systematic review of interventions and effects. Int. J. Qual Health Care. 2009;21(2):137–44. Doi: 10.1093/intqhc/mzn061.

42. Ripamonti C., Santini D., Maranzano E., et al. Management of cancer pain: ESMO clinical practice guidelines. Ann. Oncol. 2012;23(7):139–54.

43. Bennett M.I. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat. Med. 2011;25:553. Doi:10.1177/0269216310378546.

44. Bordeleau L., Pritchard K., Goodwin P., Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin. Therapeut. J. 2007;29(2):230–41. Doi:10.1016/j.clinthera.2007.02.006.

45. Kast R.E., Foley K. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur. J. Cancer Care (Engl). 2007;16:351–54. Doi:10.1111/j.1365-2354.2006.00760.x.

46. Riechelmann R.P., Burman D., Tannock I.F., et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am. J. Hosp. Pallat. Care. 2012;27:106–10. Doi:10.1177/1049909109345685.

47. Breitbart W., Alici-Evcimen Y. Update on psychotropic medications for cancer-related fatigue. J. Natl. Compr. Canc. Netw. 2007;5:1081–91.

48. Minton O., Richardson A., Sharpe M., et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J. Natl. Cancer Inst. 2008;100:1155–66. Doi: 10.1093/jnci/djn250.

49. Breitbart W., Alici Y. Psychostimulants for cancer-related fatigue. J. Natl. Compr. Canc. Netw. 2010;8:933–42.

50. Minton O., Richardson A., Sharpe M., et al. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J. Pain Symptom Manage. 2011;41:761–67. Doi:10.1016/j.jpainsymman.2010.06.020.

51. Bennett M.I., Laird B., Van Litsenburg C., Nimour M.Pregabalin for management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med. 2013;5:132–36. Doi:10.1111/pme.12212.


Об авторах / Для корреспонденции


Автор для связи: Ю.Н. Зубкова, врач-психиатр, отдел функциональной диагностики, интенсивной терапии и реабилитации, НМИЦ онкологии им. Н.Н. Блохина, Москва, Россия;e-mail: kostenay@mail.ru
Адрес: 115478, Россия, Москва, Каширское шоссе, 24


Похожие статьи


Бионика Медиа